Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 10:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post-Menopausal Osteoporosis Clear all
Completed Phase 2 Interventional

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

NCT00165204
View directory record Official record
Conditions
Menopause, Postmenopausal Bone Loss, Breast Cancer
Interventions
Tibolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

NCT01732770
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 3 Interventional

Calcium Supplementation in Postmenopausal Women

NCT00172172
View directory record Official record
Conditions
Osteoporosis
Interventions
PTH/Calcium, PTH/placebo, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
17
States / cities
Rancho Cucamonga, California • Lake Worth, Florida • Coeur d'Alene, Idaho + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444
View directory record Official record
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

NCT00172107
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 1997
U.S. locations
15
States / cities
Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 3 Interventional

Open Label Extension

NCT00172120
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
9
States / cities
Beverly Hills, California • Chicago, Illinois • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment

NCT00551174
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Gainesville, Georgia • St Louis, Missouri • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women

NCT00222872
View directory record Official record
Conditions
Osteoporosis, Osteoporosis, Postmenopausal
Interventions
Parathyroid Hormone-related Protein, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 3 Interventional

Open Label Extension Study of PREOS

NCT00172133
View directory record Official record
Conditions
Osteoporosis
Interventions
ALX1-11 (drug)
Drug
Lead sponsor
Shire
Industry
Eligibility
45 Years and older · Female only
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Not applicable Interventional

Optimizing Body Composition & Health After Breast Cancer

NCT00659906
View directory record Official record
Conditions
Breast Neoplasm, Osteoporosis, Postmenopausal
Interventions
Resistance Exercise, Flexibility Training
Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jun 10, 2026, 10:09 AM EDT
Terminated Phase 2 Interventional Results available

Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women

NCT03165747
View directory record Official record
Conditions
Menopausal Osteoporosis
Interventions
VSL#3, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Jun 10, 2026, 10:09 AM EDT
Withdrawn Phase 2 Interventional

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes

NCT06973109
View directory record Official record
Conditions
Osteoporosis, Post-menopausal
Interventions
Romosozumab, Alendronate (Fosamax), Placebo Romosozumab, Placebo Alendronate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional

Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo

NCT00532246
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
5
States / cities
La Jolla, California • Menlo Park, California • Oakland, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quercetin's Effect on Bone Health and Inflammatory Markers

NCT05371340
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Quercetin (500 mg), Placebo (500 mg)
Dietary Supplement · Other
Lead sponsor
Kennesaw State University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women

NCT00244907
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Genistein vs Risedronate
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determination of Adipocyte Parameters in Iliac Crest Biopsies From Post Menopausal Women

NCT00443716
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
estrogen
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1985 – 1989
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

NCT00503113
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva], Alendronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
60 Years and older · Female only
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Riverside, California • Lakewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density

NCT01406548
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
BPS804 20mg/Kg, Placebo to 20mg/Kg BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Moringa Oleifera on Bone Density

NCT03026660
View directory record Official record
Conditions
Osteoporosis, Osteopenia, Postmenopausal Osteoporosis
Interventions
Moringa Oleifera, Cabbage Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
60 Years to 70 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover

NCT01653275
View directory record Official record
Conditions
Osteoporosis, Postmenopausal Bone Loss
Interventions
Mediterranean Diet
Other
Lead sponsor
UConn Health
Other
Eligibility
65 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Results available

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva

NCT00081653
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Loma Linda, California • Lakewood, Colorado • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional

A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis

NCT02598440
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate, Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tempe, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional

PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia

NCT02598453
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Ibandronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Female only
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
60
States / cities
Montgomery, Alabama • Lake Havasu City, Arizona • Paradise Valley, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 10:09 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)

NCT00303485
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Placebo, Vitamin D and calcium supplementation, ibandronate [Bonviva/Boniva]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
65 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Jun 10, 2026, 10:09 AM EDT